Amanda Leiter, MD, MSCR

Dr. Leiter is an endocrinologist and cancer researcher whose work focuses on improving outcomes for patients with cancer and diabetes. Dr. Leiter completed a T32 Cancer Prevention and Control at the Icahn School of Medicine at Mount Sinai, where she developed expertise in analyzing large national cancer datasets to study the intersection of metabolic diseases and cancer. Dr. Leiter’s current research program focuses on improving diabetes care in the context of cancer survivorship. Dr. Leiter is currently developing simulation models (running “simulated” clinical trials) to elucidate optimal diabetes treatment strategies in cancer survivors, with a current focus on breast cancer and prostate cancer. In both her research and clinical practice, Dr. Leiter is also interested in further understanding and improving management of endocrine complications of cancer treatments.

Leiter A, Kong CY, Gould MK, Kale MS, Veluswamy RJ, Smith CB, Mhango G, Huang BZ, Wisnivesky JP, Sigel K. The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with comorbidities: A simulation study. PLoS one. 2022 Nov 15;17(11):e0263911. Doi: 10.1371/journal.pone.0263911. PMID: 36378625. 

Leiter A, Stephens C, Mhango G, Kong CY, Sigel K,  Lin JJ, Gallagher EJ, LeRoith D, Wisnivesky JP. Impact of diabetes on stage I lung cancer treatment patterns and prognosis in older adults: A population-based cohort study. Heliyon. 2023 Jul 5;9(7):e17969. Doi: 10.1016/j.heliyon.2023.e17969. PMID: 37455987. 

Yang A, Mhango G, Kong CY, Lin JJ, Wisnivesky JP, Leiter A. National Statin Prescription Disparities in Patients with Breast Cancer and Diabetes for Primary Cardiovascular Disease Prevention. Frontiers in Oncology. 24 Nov 6;14:1483918. doi: 10.3389/fonc.2024.1483918. PMID: 39568566.